WHO is partnering with the Drug Regulatory Authority of Pakistan to deliver pharmacovigilance training for 100 healthcare experts, a move aimed at strengthening the monitoring of medicine and vaccine safety across the country. The programme focuses on building practical skills so clinicians, pharmacists and regulators can better detect, report and assess adverse events.
The pharmacovigilance training will equip participants with standardized tools and reporting practices that enhance the national ability to evaluate the effectiveness and safety of products administered to patients. By improving signal detection and data interpretation, the initiative supports more timely regulatory decisions and safer patient care.
For Pakistan’s public health system, investing in qualified personnel through targeted pharmacovigilance training helps reinforce public confidence in immunisation and treatment programmes. Trained experts will support stronger surveillance networks across provinces and improve coordination between healthcare providers and the regulator.
The collaboration between WHO and the Drug Regulatory Authority of Pakistan underscores a commitment to sustained capacity building in drug safety. Strengthening these systems through focused training of 100 healthcare experts aims to ensure that medicines and vaccines used nationwide remain both safe and effective for patients.
